A Wireless Diabetes Implant Kept Islet Cells Working for 90 Days—Here’s Why That Matters
- Apr 12
- 4 min read
For many people living with type 1 diabetes, “treatment” is not a once-a-day routine. It can mean constant decision-making—checking blood sugar, calculating carbs, correcting highs, preventing lows, and taking insulin repeatedly. That daily burden is why researchers have long pursued a different goal: instead of injecting insulin from the outside, could we restore insulin production from the inside—safely, and for the long term?
A newly reported implant concept from MIT, takes another step in that direction. It centers on insulin-producing cells (islet cells) placed inside a protective device that aims to keep them alive and functioning while shielding them from immune rejection. In animal studies, the encapsulated islet cells survived and stayed functional for at least about 90 days (three months) and produced enough insulin to control blood sugar.
That “immune rejection” point is not a small detail. Traditional islet cell transplantation has been used in clinical care, but it generally requires immune-suppressing drugs to stop the body from attacking the transplanted cells. The research goal described here is to deliver the benefits of cell therapy without that immune suppression, which can be debilitating for some patients.
“Islet cell therapy can be a transformative treatment for patients. However, current methods also require immune suppression, which for some people can be really debilitating,” says Daniel Anderson, a professor in MIT’s Department of Chemical Engineering and a member of MIT’s Koch Institute for Integrative Cancer Research and Institute for Medical Engineering and Science. “Our goal is to find a way to give patients the benefit of cell therapy without the need for immune suppression.”
So what’s different about this implant approach? Oxygen. Encapsulating cells can protect them—but it can also starve them, because the protective barrier may limit oxygen delivery. This design includes an on-board oxygen generator, and the device is powered wirelessly by an external antenna placed on the skin that transfers energy to the implant. The intent is to keep the islet cells in a healthier environment so they continue producing insulin instead of failing after days or weeks.
The story also explains that an earlier generation of the device demonstrated shorter-term function (about a month in mice), and the newer work focused on durability upgrades—making the device more waterproof, more resilient, and improving electronics to deliver more power to oxygen production. In translational medicine, those engineering details are often what separate a “cool concept” from something that might actually scale into longer trials.
You might be wondering: Does it work well enough to control blood sugar? In the animal experiments described, the implanted donor islet cells produced enough insulin to keep blood sugar in a healthy range, and the system remained functional for at least those ~90 days. The story also notes similar experiments with stem-cell-derived islets, which could matter because supply constraints are one of the real bottlenecks in cell therapy.
It’s important to be realistic about what this does not mean yet. A three-month result in animals isn’t a commercial product, and it isn’t a guarantee of long-term, always-on glucose control in humans. The researchers explicitly describe the next horizon as making the device last much longer—potentially up to two years or more—and that kind of durability jump typically requires many iterations, safety checks, and staged clinical testing.
Still, the reason this story is so hopeful is that it addresses two hard problems at once: immune rejection and oxygen starvation. If those constraints can be managed in people, “insulin on demand” becomes less theoretical. Even partial relief from the daily injection burden could be meaningful, especially for people who struggle with hypoglycemia risk, glucose variability, or access barriers to advanced diabetes technologies.
If you’re tracking diabetes innovation, here are the milestones that would convert this from exciting research into a near-term clinical storyline: longer-duration implants in larger animals, evidence the system stays stable and safe over many months, and early human studies that look at both glucose control and device reliability. Each of those steps matters because the end goal isn’t simply “cells that make insulin.” It’s a therapy that works day after day, without adding new risks that outweigh the benefit.
For now, the best takeaway is grounded optimism: this is a credible engineering approach with clear proof-of-concept progress, reported with measurable duration (90 days) and a plausible mechanism (wireless oxygen support). It’s exactly the kind of incremental, durable advance that can eventually change what “living with type 1 diabetes” looks like.
The research was funded, in part, by Breakthrough TID, the Leona M. and Harry B. Helmsley Charitable Trust, the National Institutes of Health, and a Koch Institute Support (core) Grant from the National Cancer Institute.
Original source: https://news.mit.edu/2026/implantable-islet-cells-could-control-diabetes-without-insulin-injections-0326
About Direct Diabetes
Direct Diabetes has been helping people with diabetes for nearly 30 years by mailing the supplies they need directly to their home, and helping them avoid the hassle of having to go to a pharmacy. From Continuous Glucose Monitors (CGMs) to insulin pumps and testing supplies, our goal is to take the stress out of managing diabetes so patients can focus on living healthier, fuller lives. We work directly with doctors and insurance companies to make the process simple and affordable.
📞 Contact Us: 480-998-5551
🌐 Website: DirectDiabetes.com
📲 Follow Us:
This content is for informational purposes only and should not be taken as medical advice. Always consult a qualified healthcare provider about any questions or concerns regarding your health or treatment options.
